Citations

Clear

112 citation(s) found for "Fasching, PA".

Rare Copy Number Variants (CNVs) and Breast Cancer Risk
Dorling, Leila , Bola, Manjeet, Wang, Qin , Andrulis, Irene L. , Antonenkova, Natalia, Aronson, Kristan J. , Freeman, Laura Beane, Beckmann, Matthias W. , Bojeson, Stig, Chang‐Claude, Jenny , Chenevix‐Trench, Georgia , Collaborators, NBCS, Collée, J. Margriet, Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, Hahen, Eric, Haiman, Christopher A. , Hoppe, Reine, Investigators, ACTB, Investigators, kConFab, Jager, Agnes , Johnson, Nichola , Keeman, Renske , Ko, Yon‐Dschun, Kosma, Veli‐Matti , Kristensen, Vessela N. , Kubelka‐Sabit, Katerina , Kurian, Alison, Larson, Nicole L. , Linet, Martha S. , Łukomska, Alicja, Mannermaa, Arto , Mavroudis, Dimitrios, Park‐Simon, Tjoung‐Won , Peterlongo, Paolo , Plaseska-Karanfilska, Dijana, Sawyer, Elinor J. , Schmutzler, Rita K., Shibli, Rana , Soucy, Penny, Tomlinson, Ian , Vachon, Celine M. , Wendt, Camilla, Yang, Xiaohong R. , Easton, Douglas F. , Peterlongo, Paolo , Evans, D Gareth , Chenevix-Trench, Georgia , Sawyer, Elinor J , Dennis, Joe , Tyrer, Jonathan P. , Walker, Logan C. , Michailidou, Kyriaki , Ahearn, Thomas U. , Anton‐Culver, Hoda , Arndt, Volker , Behrens, Sabine , Benı́tez, Javier , Bermisheva, Marina , Bojesen, Stig E. , Brenner, Hermann , Castelao, Jose E. , Clarke, Christine L. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Devilee, Peter , Dörk, Thilo , Dossus, Laure , Eliassen, A. Heather , Eriksson, Mikael , Figueroa, Jonine D. , Fletcher, Olivia , Fritschi, Lin , Gabrielson, Marike , Gago-Domínguez, Manuela , García‐Closas, Montserrat , Giles, Graham G. , González‐Neira, Anna , Guénel, Pascal , Hall, Per N , Hollestelle, Antoinette , Hoppe, Reiner , Hopper, John L. , Howell, Anthony , Jakubowska, Anna , John, Esther M. , Jones, Michael E. , Jung, Audrey , Kaaks, Rudolf , Хуснутдинова, Э. К. , Kitahara, Cari M. , Koutros, Stella , Kraft, Peter , Lambrechts, Diether , Manoukian, Siranoush , Margolin, Sara , Milne, Roger L. , Muranen, Taru , Murphy, Rachel A. , Nevanlinna, Heli , Olson, Janet E. , Olsson, Håkan , Perou, Charles M. , Pylkäs, Katri , Rennert, Gad , Saloustros, Emmanouil , Sandler, Dale P. , Schmidt, Marjanka K. , Smeets, Ann , Southey, Melissa C. , Swerdlow, Anthony J. , Tamimi, Rulla M. , Taylor, Jack A. , Teras, Lauren R. , Terry, Mary Beth , Troester, Melissa A. , Truong, Thérèse , Vachon, Celine M. , Wendt, Camilla, Winqvist, Robert , Wolk, Alicja , Zheng, Wei , Ziogas, Argyrios , Simard, Jacques , Dunning, Alison M. , Pharoah, Paul D.P.

Mayo Clinic

No container title available | June 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-602209/v1 Get It

Abstract BackgroundCopy number variants (CNVs) are pervasive in the human genome but potential disease associations with rare CNVs have not been comprehensively assessed in large datasets. We analysed rare CNVs in genes and non-coding regions for 86,788 breast cancer cases and 76,122 controls of European ancestry with genome-wide array data.ResultsGene burden tests detected the strongest association for deletions in BRCA1 (P= 3.7E-18). Nine other genes were associated with a p-value < 0.01 including known susceptibility genes CHEK2 (P= 0.0008), ATM (P= 0.002) and BRCA2 (P= 0.008). Outside the known genes we detected associations with p-values < 0.001 for either overall or subtype-specific breast cancer at nine deletion regions and four duplication regions. Three of the deletion regions were in established common susceptibility loci.ConclusionsThis is the first genome-wide analysis of rare CNVs in a large breast cancer case-control dataset. We detected associations with exonic deletions in established breast cancer susceptibility genes. We also detected suggestive associations with non-coding CNVs in known and novel loci with large effects sizes. Larger sample sizes will be required to reach robust levels of statistical significance.
Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?
Park, JooYong , Choi, Ji‐Yeob , Chung, Seokang , Song, Nan , Park, Sue K. , Han, Wonshik , Noh, Dong‐Young , Ahn, Sei-Hyun, Lee, Jong Won, Kim, Mi Kyung , Jee, Sun Ha , Wen, Wanqing , Bolla, Manjeet K. , Wang, Qin , Michailidou, Kyriaki , Shah, Mitul , Conroy, Don, Harrington, Patricia, Mayes, Rebecca , Hall, Per , Patel, Alpa V. , Couch, Fergus J. , Sawyer, Elinor J. , Roylance, Rebecca , Bojesen, Stig E. , Flyger, Henrik, Lambrechts, Diether , Baten, Adinda , Matsuo, Keitaro , Ito, Hidemi , Guénel, Pascal , Keeman, Renske , Schmidt, Marjanka K. , Wu, Anna H. , Tseng, Chiu-Chen, Cox, Angela , Investigators, kConFab, Andrulis, Irene L. , Hopper, John L., Wu, Pei‐Ei , Shen, Chen‐Yang , Fasching, Peter A. , Ekici, Arif B. , Muir, Kenneth, Brenner, Hermann , Arndt, Volker , Jones, Michael E. , Swerdlow, Anthony J, Hoppe, Reiner , Ko, Yon-Dschun, Hartman, Mikael , Li, Jingmei , Mannermaa, Arto, Hartikainen, Jaana M. , Benítez, Javier, Haiman, Christopher A. , Dörk, Thilo , Bogdanova, Natalia , Teo, Soo‐Hwang , Taib, Nur Aishah Mohd , Fletcher, Olivia, Johnson, Nichola , Grip, Mervi, Winqvist, Robert , Nevanlinna, Heli , Lindblom, Annika , Wendt, Camilla, Kristensen, Vessela N. , Collaborators, NBCS, Tollenaar, Rob A.�E.�M. , Heemskerk‐Gerritsen, Bernadette A. M. , Bonanni, Bernardo , Hamann, Ute, Manoochehri, Mehdi, Martinez, Maria Elena, Easton, Douglas F., Yoo, Keun-Young, Lambrechts, Diether , Song, Nan , Park, Sue K , Kim, Mi Kyung , Dennis, Joe , Michailidou, Kyriaki , Hall, Per N , Matsuo, Keitaro , Ito, Hidemi , Keeman, Renske , Schmidt, Marjanka K , Fasching, Peter A , Brenner, Hermann , Arndt, Volker , Hartikainen, Jaana M , Dörk, Thilo , Bogdanova, Natalia V , Johnson, Nichola , Nevanlinna, H , Heemskerk-Gerritsen, Bernadette A M , Bonanni, Bernardo , Lambrechts, Diether , Teo, Soo H , Jones, Michael E , Lambrechts, Diether , Cox, Angela , Guénel, Pascal , Hartman, Mikael , Li, Jingmei , Ekici, Arif B , Bojesen, Stig E , Lindblom, Annika , Mohd Taib, Nur Aishah , Sawyer, Elinor J , Choi, Jaesung , Czene, Kamila , Teras, Lauren R. , Couch, Fergus J. , Olson, Janet E. , Truong, Thérèse , Cross, Simon S. , Investigators, kConFab, Southey, Melissa C. , Lophatananon, Artitaya , Ko, Yon‐Dschun, Mannermaa, Arto , González‐Neira, Anna , Fletcher, Olivia , Blomqvist, Carl , Wendt, Camilla, Collaborators, NBCS, Radice, Paolo , Manoochehri, Mehdi, Lacey, James V. , Dunning, Alison M. , Pharoah, Paul D.P. , Kang, Daehee

Mayo Clinic

Cancers | May 14, 2021 | Volume: 13 | Issue: 10 | Pages: 2370

10.3390/cancers13102370 | PMID 34069208 Get It

In this study we aim to examine gene–environment interactions (GxEs) between genes involved with estrogen metabolism and environmental factors related to estrogen exposure. GxE analyses were conducted with 1970 Korean breast cancer cases and 2052 controls in the case-control study, the Seoul Breast Cancer Study (SEBCS). A total of 11,555 SNPs from the 137 candidate genes were included in the GxE analyses with eight established environmental factors. A replication test was conducted by using an independent population from the Breast Cancer Association Consortium (BCAC), with 62,485 Europeans and 9047 Asians. The GxE tests were performed by using two-step methods in GxEScan software. Two interactions were found in the SEBCS. The first interaction was shown between rs13035764 of NCOA1 and age at menarche in the GE|2df model (p-2df = 1.2 × 10−3). The age at menarche before 14 years old was associated with the high risk of breast cancer, and the risk was higher when subjects had homozygous minor allele G. The second GxE was shown between rs851998 near ESR1 and height in the GE|2df model (p-2df = 1.1 × 10−4). Height taller than 160 cm was associated with a high risk of breast cancer, and the risk increased when the minor allele was added. The findings were not replicated in the BCAC. These results would suggest specificity in Koreans for breast cancer risk.
Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis
Fasching, Peter A. , Yadav, Siddhartha , Wunderle, Marius , Häberle, Lothar , Hart, Steven N. , Rübner, Matthias, Polley, Eric C. , Lee, Kun Y. , Hadji, Peyman , Hübner, H., Tesch, Hans , Ettl, Johannes , Overkamp, Friedrich , Ekici, Arif B. , Volz, Bernhard , Uhrig, Sabrina , Lüftner, Diana , Müller, Volkmar , Belleville, Erik, Kolberg, Hans‐Christian , Beckmann, Matthias W. , Hartmann, Arndt , Janni, Wolfgang , Taran, Florin‐Andrei , Fehm, Tanja , Wallwiener, D. , Schneeweiß, Andreas , Chen, Chen , Hu, Chunling , Wunderle, Marius , Hart, Steven N , Polley, Eric C , Lee, Kun Y , Gnanaolivu, Rohan D., Hübner, Hanna , Lux, Michael P , Ekici, Arif B , Müller, Volkmar , Untch, Michael , Kolberg, Hans-Christian , Reis, André , Schneeweiss, Andreas , Hartkopf, Andreas D , Couch, Fergus J. , Chen, C , Yadav, Siddhartha , Fehm, Tanja , Hu, Chunling , Gnanaolivu, Rohan , Lux, Michael P. , Wallwiener, Markus , Untch, Michael , Reis, André , Wimberger, Pauline , Brucker, Sara Yvonne , Couch, Fergus J.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2021 | Volume: 39 | Issue: 15 | Pages: 1619-1630

10.1200/jco.20.01200 | PMID 33780288 Get It

PURPOSE Among patients with metastatic breast cancer (mBC), the frequency of germline mutations in cancer susceptibility genes and the clinical relevance of these mutations are unclear. In this study, a prospective cohort of patients with mBC was used to determine mutation rates for breast cancer (BC) predisposition genes, to evaluate the clinical characteristics of patients with mutations, and to assess the influence of mutations on patient outcome. PATIENTS AND METHODS Germline DNA from 2,595 patients with mBC enrolled in the prospective PRAEGNANT registry was evaluated for mutations in cancer predisposition genes. The frequencies of mutations in known BC predisposition genes were compared with results from a prospective registry of patients with nonmetastatic BC sequenced using the same QIAseq method and with public reference controls. Associations between mutation status and tumor characteristics, progression-free survival, and overall survival were assessed. RESULTS Germline mutations in 12 established BC predisposition genes (including BRCA1 and BRCA2) were detected in 271 (10.4%) patients. A mutation in BRCA1 or BRCA2 was seen in 129 patients (5.0%). BRCA1 mutation carriers had a higher proportion of brain metastasis (27.1%) compared with nonmutation carriers (12.8%). Mutations were significantly enriched in PRAEGNANT patients with mBC compared with patients with nonmetastatic BC (10.4% v 6.6%, P < .01). Mutations did not significantly modify progression-free survival or overall survival for patients with mBC. CONCLUSION Multigene panel testing may be considered in all patients with mBC because of the high frequency of germline mutations in BRCA1/2 and other BC predisposition genes. Although the prognosis of mutation carriers and nonmutation carriers with mBC was similar, differences observed in tumor characteristics have implications for treatment and for future studies of targeted therapies.
Early developmental asymmetries in cell lineage trees in living individuals
Fasching, Liana , Jang, Yeongjun , Schreiner, Jeremy D. , Tomasini, Livia , Brady, Melanie , Bae, Taejeong , Sarangi, Vivekananda , Vasmatzis, Nikolaos , Wang, Yifan , Szekely, Anna , Fernandez, Thomas , Leckman, James F. , Abyzov, Alexej , Vaccarino, Flora M. , Schreiner, Jeremy , Tomasini, Livia , Brady, Melanie V , Bae, Taejeong , Vasmatzis, Nikolaos , Wang, Yifan , Szekely, Anna , Fernandez, Thomas V , Abyzov, Alexej , Vaccarino, Flora M , Leckman, James F , Jang, Yeongjun , Tomasi, Simone

Mayo Clinic

Science | March 18, 2021 | Volume: 371 | Issue: 6535 | Pages: 1245-1248

10.1126/science.abe0981 | PMID 33737484 Get It

Genomic sleuthing spots early divergence After fertilization, the human zygote divides into two cells. Fasching et al. used genomic analysis from cellular samples taken much later in development to back-calculate the cell division trees that went before. Although the first cell division in human development looks symmetrical from the outside, the fates followed by daughter cells from each of those first two blastomeres are anything but the same. As much as 90% of blood cells are derived from just one of the first two blastomeres. Science , this issue p. 1245
Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium
Morra, Anna , Jung, Audrey , Behrens, Sabine , Keeman, Renske , Ahearn, Thomas U. , Arndt, Volker , Augustinsson, Annelie , Auvinen, Päivi , Becher, Heiko , Beckmann, Matthias W. , Bojesen, Stig E. , Bolla, Manjeet K. , Brenner, Hermann , Camp, Nicola J. , Campa, Daniele , Castelao, Jose E. , Choi, Ji‐Yeob , Cox, Angela , Easton, Douglas F. , Eccles, Diana M., Egan, Kathleen M. , Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, Gago-Domínguez, Manuela , Gapstur, Susan M. , Gaudet, Mia M. , Grip, Mervi, Guénel, Pascal , Haiman, Christopher A. , Håkansson, Niclas , Hamann, Ute, Hartman, Mikael , Heyworth, Jane , Hoppe, Reiner , Hopper, John L. , Hunter, David J. , Jager, Agnes , Jakimovska, Milena , Janni, Wolfgang , Koutros, Stella , Kristensen, Vessela N. , Lambrechts, Diether , Li, Jingmei , Lindblom, Annika , Mannermaa, Arto , Manoochehri, Mehdi, Margolin, Sara , Mariapun, Shivaani, Mavroudis, Dimitrios, Muranen, Taru , Newman, William G. , Noh, Dong‐Young , Nordestgaard, Børge G. , Obi, Nadia , Olsson, Håkan , Park‐Simon, Tjoung‐Won , Petridis, Christos , Plaseska‐Karanfilska, Dijana , Rashid, Muhammad Usman , Rennert, Gad , Rennert, Gad , Rhenius, Valerie , Romero, Atocha , Saloustros, Emmanouil , Sawyer, Elinor J. , Schneeweiß, Andreas , Schwentner, Lukas , Shah, Mitul , Shen, Chen‐Yang , Tollenaar, Rob A.�E.�M. , Tomlinson, Ian , Torres, Diana , Vachon, Celine M. , Wang, Qin , Wang, Sophia , Williams, Justin A. , Winqvist, Robert , Wu, Anna H. , Yoo, Keun-Young, Yu, Jyh‐Cherng , Zheng, Wei , Yang, Xiaohong R. , Eliassen, A. Heather , García‐Closas, Montserrat , Teo, Soo‐Hwang , Chang‐Claude, Jenny , Eccles, Diana , Khaw, Kay‐Tee , Lambrechts, Diether , Arndt, Volker , Augustinsson, Annelie , Brenner, Hermann , Camp, Nicola J , Canzian, Federico , Cox, Angela , Dunning, Alison M , Evans, D Gareth , Fasching, Peter A , Gago-Dominguez, Manuela , García-Sáenz, José A , Gaudet, Mia M , Giles, Graham G , Guénel, Pascal , Hall, Per N , Hart, Steven N , Hartman, Mikael , Ito, Hidemi , Jager, Agnes , Jakubowska, Anna , Janni, Wolfgang , Kaaks, Rudolf , Kapoor, Pooja Middha , Koutros, Stella , Lambrechts, Diether , Li, Jingmei , Matsuo, Keitaro , Milne, Roger L , Muranen, Taru A , Newman, William G , Park-Simon, Tjoung-Won , Pharoah, Paul D P , Rennert, Gad , Rennert, Gad , Rhenius, Valerie , Romero, Atocha , Saloustros, Emmanouil , Schneeweiss, Andreas , Scott, Christopher , Southey, Melissa C , Stram, Daniel O. , Tamimi, Rulla M , Tomlinson, Ian , Torres, Diana , Vachon, Celine M. , Wolk, Alicja , Ziogas, Argyrios , Holmes, Michelle D , García-Closas, Montserrat , Teo, Soo H , Schmidt, Marjanka K , Chang-Claude, Jenny , Lambrechts, Diether , Behrens, Sabine , Eccles, Diana , Keeman, Renske , Zheng, Wei , Wang, Sophia S , Jung, Audrey Y , Becher, Heiko , Eliassen, A Heather , Håkansson, Niclas , Rashid, Muhammad U , Bojesen, Stig E , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Sawyer, Elinor J , Anton‐Culver, Hoda , Freeman, Laura E. Beane , Blomqvist, Carl , Briceño, Ignacio , Brucker, Sara Yvonne , Canzian, Federico , Chanock, Stephen Jacob , Clarke, Christine L. , Couch, Fergus J. , Cross, Simon S. , Czene, Kamila , Dörk, Thilo , Dunning, Alison M. , Dwek, Miriam , García-Sáenz, José Á. , Giles, Graham G. , Han, Sileny , Hart, Steven N. , Ito, Hidemi , Jakubowska, Anna , Kaaks, Rudolf , Kang, Daehee , Middha, Pooja , Kitahara, Cari M. , Kraft, Peter , Lacey, James V. , Marchand, Loı̈c Le , Lubiński, Jan , Lush, Michael J. , Manoochehri, Mehdi, Matsuo, Keitaro , Milne, Roger L. , Olshan, Andrew F. , Pharoah, Paul D.P. , Presneau, Nadège , Scott, Christopher G. , Shu, Xiao‐Ou , Southey, Melissa C. , Tamimi, Rulla M. , Tapper, William , Troester, Melissa A. , Truong, Thérèse , Wolk, Alicja , Ziogas, Argyrios , Schmidt, Marjanka K.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 26, 2021 | Volume: 30 | Issue: 4 | Pages: 623-642

10.1158/1055-9965.epi-20-0924 | PMID 33500318 Get It

Abstract Background: It is not known whether modifiable lifestyle factors that predict survival after invasive breast cancer differ by subtype. Methods: We analyzed data for 121,435 women diagnosed with breast cancer from 67 studies in the Breast Cancer Association Consortium with 16,890 deaths (8,554 breast cancer specific) over 10 years. Cox regression was used to estimate associations between risk factors and 10-year all-cause mortality and breast cancer–specific mortality overall, by estrogen receptor (ER) status, and by intrinsic-like subtype. Results: There was no evidence of heterogeneous associations between risk factors and mortality by subtype (Padj &gt; 0.30). The strongest associations were between all-cause mortality and BMI ≥30 versus 18.5–25 kg/m2 [HR (95% confidence interval (CI), 1.19 (1.06–1.34)]; current versus never smoking [1.37 (1.27–1.47)], high versus low physical activity [0.43 (0.21–0.86)], age ≥30 years versus &lt;20 years at first pregnancy [0.79 (0.72–0.86)]; &gt;0–&lt;5 years versus ≥10 years since last full-term birth [1.31 (1.11–1.55)]; ever versus never use of oral contraceptives [0.91 (0.87–0.96)]; ever versus never use of menopausal hormone therapy, including current estrogen–progestin therapy [0.61 (0.54–0.69)]. Similar associations with breast cancer mortality were weaker; for example, 1.11 (1.02–1.21) for current versus never smoking. Conclusions: We confirm associations between modifiable lifestyle factors and 10-year all-cause mortality. There was no strong evidence that associations differed by ER status or intrinsic-like subtype. Impact: Given the large dataset and lack of evidence that associations between modifiable risk factors and 10-year mortality differed by subtype, these associations could be cautiously used in prognostication models to inform patient-centered care.
Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers
Glubb, Dylan M. , Thompson, Deborah J. , Aben, Katja K.H. , Alsulimani, Ahmad , Amant, Frédéric , Annibali, Daniela , Barricarte, Aurelio , Beckmann, Matthias W. , Bermisheva, Marina , Bernardini, Marcus Q. , Bischof, Katharina , Bodelón, Clara , Brand, Alison H. , Brinton, Louise A. , Bruinsma, Fiona , Burghaus, Stefanie , Cai, Hui , Carney, Michael E. , Chen, Chu , Chen, Xiao Qing, Chen, Zhihua , Cunningham, Julie M. , Vivo, Immaculata De , Dörk, Thilo , Edwards, Todd, Ekici, Arif B. , Ewing, Ailith , Fasching, Peter A. , Ferguson, Sarah, Flanagan, James M. , Fostira, Florentia, Gao, Bo , Gaudet, Mia M. , Gawełko, Jan , Goodman, Marc T. , Harter, Philipp , Hein, Alexander , Hildebrandt, Michelle A.T., Hillemanns, Peter , Høgdall, Claus , Holliday, Elizabeth , Huntsman, David G. , Huzarski, Tomasz , Jones, Michael E. , Kelley, Joseph L., Killeen, Jeffrey , Klapdor, Rüdiger , Köbel, Martin , Konopka, Bożena , Konstantopoulou, Irene , Kopperud, Reidun Kristin, Koti, Madhuri , Lambrechts, Diether , Lele, Shashikant , Lester, Jenny, Li, Andrew J., Liang, Dong , Liebrich, Clemens, Lipworth, Loren , Lissowska, Jolanta , Lu, Karen H., May, Taymaa, McGuire, Valerie , McNeish, Iain A. , Menon, Usha , Moysich, Kirsten B. , Odunsi, Kunle , Olsson, Håkan , Oršulić, Sandra , Osório, Ana , Park‐Simon, Tjoung‐Won , Pearce, Celeste Leigh, Podgórska, Agnieszka , Ramus, Susan J. , Riggan, Marjorie J. , Rothstein, Joseph H. , Runnebaum, Ingo B. , Scott, Rodney J. , Sellers, Thomas A. , Sieh, Weiva , Śpiewankiewicz, Beata, Sutphen, Rebecca , Teo, Soo‐Hwang , Thompson, Pamela J., Titus, Linda , Tone, Alicia , Edwards, Digna Velez, Vergote, Ignace , Wang, Zhaoming , Wang‐Gohrke, Shan , Group, for the OPAL Study, Group, for the AOCS, Whittemore, Alice S. , Wu, Xifeng , Wu, Anna H. , O’Mara, Tracy A. , Lu, Karen H. , Lambrechts, Diether , Barricarte, Aurelio , Bischof, Katharina , Bodelon, Clara , Brenton, James D , Brinton, Louise A , Buchanan, Daniel D , Cunningham, Julie M , De Vivo, Immaculata , Fazio, Anna de , Doherty, Jennifer A , Dörk, Thilo , Dunning, Alison M , Edwards, Todd , Ewing, Ailith , Fasching, Peter A , Flanagan, James M , Friedenreich, Christine M , Gaudet, Mia M , Gawełko, Jan , Gentry‐Maharaj, Aleksandra , Giles, Graham G , Glasspool, Rosalind , Harris, Holly R , Hein, Alexander , Heitz, Florian , Hillemanns, Peter , Jakubowska, Anna , Jones, Michael E , Karlan, Beth Y , Karnezis, Anthony , Kjaer, Susanne K , Klapdor, Rüdiger , Köbel, Martin , Konstantopoulou, Irene , Kupryjanczyk, Jolanta , Lambrechts, Diether , Lissowska, Jolanta , Lu, Lingeng , McAlpine, Jessica N , McNeish, Iain A , Menon, Usha , Nevanlinna, H , Orsulic, Sandra , Palli, Domenico , Park-Simon, Tjoung-Won , Permuth, Jennifer B , Ramus, Susan J , Runnebaum, Ingo B , Sieh, Weiva , Swerdlow, Anthony J , Szafron, Lukasz M , Teo, Soo H , Thompson, Pamela J , Thomsen, Liv Cecilie Vestrheim , Titus, Linda , Tumino, Rosario , Vanderstichele, Adriaan , Vergote, Ignace , Vierkant, Robert A , Webb, Penelope M , Winham, Stacey J , Spurdle, Amanda B , Lambrechts, Diether , Moysich, Kirsten , Wang, Zhaoming , O'Mara, Tracy A , Ekici, Arif B , Amant, Frederic , Høgdall, Claus K , Huzarski, Tomasz , Brand, Alison H , Goodman, Marc T , Attia, John , Berchuck, Andrew , Bjørge, Line , Brenton, James D. , Buchanan, Daniel D. , Bützow, Ralf C. , Chanock, Stephen Jacob , Chen, Xiao Qing, Cook, Linda S. , DeFazio, Anna , Doherty, Jennifer A. , Bois, Andreas du , Dunning, Alison M. , Dürst, Matthias , Fountzilas, George , Giles, Graham G. , Glasspool, Rosalind , Gronwald, Jacek , Harris, Holly R. , Heitz, Florian , Hildebrandt, Michelle A.T. , Høgdall, Estrid , Jakubowska, Anna , Jensen, Allan , Karlan, Beth Y. , Karnezis, Anthony N. , Хуснутдинова, Э. К. , Kjær, Susanne K. , Kraft, Peter , Kupryjańczyk, Jolanta , Larson, Melissa C. , Marchand, Loı̈c Le , Macciotta, Alessandra , Mattiello, Amalia , McAlpine, Jessica N. , Modugno, Francesmary , Nevanlinna, Heli , Palli, Domenico , Pejovic, Tanja B. , Permuth, Jennifer B. , Rebbeck, Timothy R. , Risch, Harvey A. , Senz, Janine , Setiawan, Veronica Wendy , Siddiqui, Nadeem , Swerdlow, Anthony J. , Szafron, Lukasz M. , Thomsen, Liv Cecilie Vestrheim , ­Tumino, ­Rosario , Turman, Constance , Vanderstichele, Adriaan , Edwards, Digna R. Velez , Vierkant, Robert A. , Webb, Penelope M. , Group, for the OPAL Study, Group, for the AOCS, White, Emily , Winham, Stacey J. , Yannoukakos, Drakoulis , Spurdle, Amanda B.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 3, 2020 | Volume: 30 | Issue: 1 | Pages: 217-228

10.1158/1055-9965.epi-20-0739 | PMID 33144283 Get It

Abstract Background: Accumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. We aimed to identify joint endometrial and ovarian cancer risk loci by performing a meta-analysis of GWAS summary statistics from these two cancers. Methods: Using LDScore regression, we explored the genetic correlation between endometrial cancer and ovarian cancer. To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e., inverse-variance meta-analysis, colocalization, and M-values) and performed analyses stratified by subtype. Candidate target genes were then prioritized using functional genomic data. Results: Genetic correlation analysis revealed significant genetic correlation between the two cancers (rG = 0.43, P = 2.66 × 10−5). We found seven loci associated with risk for both cancers (PBonferroni &lt; 2.4 × 10−9). In addition, four novel subgenome-wide regions at 7p22.2, 7q22.1, 9p12, and 11q13.3 were identified (P &lt; 5 × 10−7). Promoter-associated HiChIP chromatin loops from immortalized endometrium and ovarian cell lines and expression quantitative trait loci data highlighted candidate target genes for further investigation. Conclusions: Using cross-cancer GWAS meta-analysis, we have identified several joint endometrial and ovarian cancer risk loci and candidate target genes for future functional analysis. Impact: Our research highlights the shared genetic relationship between endometrial cancer and ovarian cancer. Further studies in larger sample sets are required to confirm our findings.
Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea
Ruddy, Kathryn J. , Schaid, Daniel J. , Batzler, Anthony , Cecchini, Reena S. , Trabuco, Emanuel C. , Ginsburg, Elizabeth S. , Fasching, Peter A. , Vachon, Celine M. , Ganz, Patricia A. , Norman, Aaron, Trabuco, Emanuel, Vachon, Celine, Partridge, Ann H. , Norman, Aaron D. , Fehrenbacher, Louis , Stewart, Elizabeth A. , Couch, Fergus J. , Vachon, Celine M.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 29, 2020 | Volume: 113 | Issue: 8 | Pages: 1105-1108

10.1093/jnci/djaa160 | PMID 33159444 Get It

Abstract Antimullerian hormone (AMH) is a promising biomarker for ovarian reserve. In this study, we assessed AMH before and 1 year after initiation of adjuvant chemotherapy on National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology B-47 in female participants aged 42 years and younger (median age = 39 years). At baseline, median AMH was 1.2 ng/mL; 13 (4.7%) values were less than 0.1 ng/mL (the threshold for detectable levels, in the perimenopause and menopause range), and 57 values (20.6%) were less than 0.5 ng/mL. At 1 year, 215 (77.6%) were less than 0.1 ng/mL, and 264 (95.3%) were less than 0.5 ng/mL. Postchemotherapy menses were reported by 46.2% of participants. Multivariable logistic regression found that the odds of having postchemotherapy menses increased with younger age, higher body mass index, and higher prechemotherapy AMH, but not by trastuzumab administration or by the choice of chemotherapy (doxorubicin-cyclophosphamide followed by paclitaxel vs docetaxel-cyclophosphamide). We conclude that higher prechemotherapy AMH predicts a lower risk of chemotherapy-induced amenorrhea and that AMH 1 year after chemotherapy initiation is not informative in this setting because it is likely to be very low.
Abstract B37: Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer
Dicks, Ed , Song, Honglin , Ariff, Amir , Intermaggio, Maria P., Moysich, Kirsten, Odunsi, Kunle , Goode, Ellen L. , Fasching, Peter, Gayther, Simon A. , Pavanello, Marina , Bolithon, Adelyn , Pinese, Mark , Bowtell, David D.L. , Fasching, Peter, Doherty, Jennifer A. , Modugno, Francesmary , Kjær, Susanne K. , Webb, Penelope M. , Wu, Anna M. , DeFazio, Anna , James, Paul A. , Subramanian, Deepak , Campbell, Ian , Pharoah, Paul D.P. , Ramus, Susan J.

Mayo Clinic

Clinical Cancer Research | September 1, 2020 | Volume: 26 | Issue: 13_Supplement | Pages: B37-B37

10.1158/1557-3265.ovca19-b37 Get It

Abstract Improving risk prediction and prevention strategies through identifying new susceptibility genes for non-high-grade serous ovarian cancer (non-HGS) would represent an important advance in reducing incidence and mortality. Epithelial ovarian cancer (EOC) has five main histotypes that have distinct pathologies, molecular changes, clinical characteristics, and tissues of origin. They are classified as high-grade serous (HGS), low-grade serous (LGS), clear-cell (CCC), endometrioid (END), and mucinous (MUC). A family history of breast or ovarian cancer is the strongest single risk factor for EOC. Germline mutations in the high-penetrance susceptibility genes BRCA1 and BRCA2 confer EOC risks of 44% and 17% by age 80, respectively. Only 40% of the excess familial risk is known, suggesting there are many other susceptibility genes yet unidentified. The non-HGS histotypes are poorly studied due to limited sample size within individual studies. Thus, families of cases with non-HGS tumors have few risk prediction options. Whole-exome sequencing (WES) analysis was performed on 251 non-HGS cases (56 LGS, 55 CCC, 117 END, 23 MUC). Cases were screened negative for BRCA1/2 mutations and selected for a family history of ovarian or breast cancer, or young onset (&lt;45 years) of ovarian cancer. WES identified 1,278 genes with rare predicted truncating mutation in at least one case. Predicted truncating mutations in cases were compared to 171,584 controls from the Exome Aggregation Consortium (ExAC) and the Genome Aggregation Database (gnomAD). Gene-set enrichment analysis showed enrichment for genes involved in the DNA repair pathway (p=3.08 × 10−7). Twenty-five candidate genes (including 4 DNA repair genes) were selected for validation by targeted sequencing. Five genes important in HGS (BRIP1, FANCM, PALB2, RAD51C, RAD51D) as well as two additional candidates (XRCC2 and XRCC3) were also sequenced. Targeted sequencing was performed on 1,779 cases (669 END, 356 CCC, 327 LGS, 427 MUC) and 1,863 controls from studies in the Ovarian Cancer Association Consortium (OCAC). Library preparation and target enrichment was performed using the Fluidigm Juno System and Illumina sequencing was performed on a NovaSeq 6000 Sequencing System. A case-control analysis of predicted truncating variants in the 32 genes was performed. Using a minimum alternate allele frequency of 30%, we identified a higher frequency of mutations in non-HGS cases than controls in ERCC6 (p=0.034) and IL31RA (p=0.034). ERCC6 is involved in DNA repair and IL31RA is a cytokine receptor. Sanger sequencing validation of variants to confirm these results is ongoing. Several other genes showed suggestive higher frequencies of mutations in cases than controls. A larger case control analysis will be performed to confirm those findings. Identifying novel susceptibility genes for non-HGS may have clinical impact by reducing disease-associated mortality through improving risk prediction, identifying prevention strategies, and developing new targeted treatments. Citation Format: Marina Pavanello, Ed Dicks, Honglin Song, Amir Ariff, Adelyn Bolithon, Maria P. Intermaggio, Mark Pinese, Kirsten Moysich, Kunle O. Odunsi, Ellen Goode, David D. Bowtell, Peter Fasching, Jennifer A. Doherty, Francesmary Modugno, Susanne K. Kjær, Penelope M. Webb, Anna Wu, Anna deFazio, Ovarian Cancer Association Consortium, Paul James, Deepak Subramanian, Ian Campbell, Simon A. Gayther, Paul D.P. Pharoah, Susan J. Ramus. Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr B37.
Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
Annibali, Daniela , Ashton, Katie A. , Auer, Paul L. , Beckmann, Matthias W. , Black, Amanda , Brinton, Louise A. , Buchanan, Daniel D. , Chen, Chu , Chen, Maxine , Cheng, Timothy, Crous‐Bou, Marta , Vivo, Immaculata De , Dörk, Thilo , Dowdy, Sean C. , Easton, Douglas F. , Ekici, Arif B. , Fasching, Peter A. , García‐Closas, Montserrat , Gaudet, Mia M. , Goode, Ellen L. , Gorman, Maggie, Haiman, Christopher A. , Hankinson, Susan E. , Hein, Alexander , Hillemanns, Peter , Hodgson, Shirley, Høivik, Erling A. , Holliday, Elizabeth , Hunter, David J., Lambrechts, Diether , Liang, Xiaolin , Lindblom, Annika , Lissowska, Jolanta , Magliocco, Anthony M., Martin, Lynn , McEvoy, Mark , Mints, Miriam, Nassir, Rami , Otton, Geoffrey, Palles, Claire , Pooler, Loreall , Proietto, Tony, Rübner, Matthias, Runnebaum, Ingo B. , Sacerdote, Carlotta , Sarto, Gloria E., Scott, Rodney J. , Shah, Mitul , Sheng, Xin , Tomlinson, Ian , Trovik, Jone , Wang, Zhaoming , Wentzensen, Nicolas , Xia, Lucy , Webb, Penelope M. , Thompson, Deborah J. , Glubb, Dylan M., O’Mara, Tracy A. , Lambrechts, Diether , Buchanan, Daniel D , Chen, Chu , De Vivo, Immaculata , Dörk, Thilo , Fasching, Peter A , Friedenreich, Christine M , Gaudet, Mia M , Goode, Ellen L , Lu, Lingeng , Sacerdote, Carlotta , Shu, Xiao-Ou , Wang, Zhaoming , Wentzensen, Nicolas , Xiang, Yong‐Bing , Yu, Herbert , Spurdle, Amanda B , O'Mara, Tracy A , Lambrechts, Diether , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Lissowska, Jolanta , Lambrechts, Diether , García-Closas, Montserrat , Ekici, Arif B , Nassir, Rami , Palles, Claire , Lindblom, Annika , Kho, Pik Fang , Amant, Frédéric , Attia, John , Chanock, Stephen Jacob , Cook, Linda S. , Czene, Kamila , Dennis, Joe , Dunning, Alison M. , Dürst, Matthias , Fridley, Brooke L. , Giles, Graham G. , Hall, Per N , Hankinson, Susan E. , Jones, Angela, Kraft, Peter , Krakstad, Camilla , Marchand, Loı̈c Le , Long, Jirong , Milne, Roger L. , Mints, Miriam , Rebbeck, Timothy R. , Renner, Stefan P. , Risch, Harvey A. , Schumacher, Fredrick R. , Setiawan, Veronica Wendy , Shu, Xiao‐Ou , Southey, Melissa C. , Tham, Emma , Turman, Constance , Tyrer, Jonathan P. , Berg, David Van Den , Yang, Hannah , Yu, Kai , Zheng, Wei , Spurdle, Amanda B.

Mayo Clinic

International Journal of Cancer | July 13, 2020 | Volume: 148 | Issue: 2 | Pages: 307-319

10.1002/ijc.33206 | PMID 32851660 Get It

Abstract Blood lipids have been associated with the development of a range of cancers, including breast, lung and colorectal cancer. For endometrial cancer, observational studies have reported inconsistent associations between blood lipids and cancer risk. To reduce biases from unmeasured confounding, we performed a bidirectional, two‐sample Mendelian randomization analysis to investigate the relationship between levels of three blood lipids (low‐density lipoprotein [LDL] and high‐density lipoprotein [HDL] cholesterol, and triglycerides) and endometrial cancer risk. Genetic variants associated with each of these blood lipid levels ( P < 5 × 10 −8 ) were identified as instrumental variables, and assessed using genome‐wide association study data from the Endometrial Cancer Association Consortium (12 906 cases and 108 979 controls) and the Global Lipids Genetic Consortium (n = 188 578). Mendelian randomization analyses found genetically raised LDL cholesterol levels to be associated with lower risks of endometrial cancer of all histologies combined, and of endometrioid and non‐endometrioid subtypes. Conversely, higher genetically predicted HDL cholesterol levels were associated with increased risk of non‐endometrioid endometrial cancer. After accounting for the potential confounding role of obesity (as measured by genetic variants associated with body mass index), the association between genetically predicted increased LDL cholesterol levels and lower endometrial cancer risk remained significant, especially for non‐endometrioid endometrial cancer. There was no evidence to support a role for triglycerides in endometrial cancer development. Our study supports a role for LDL and HDL cholesterol in the development of non‐endometrioid endometrial cancer. Further studies are required to understand the mechanisms underlying these findings.
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Talhouk, Aline , Wang, Chen , Budden, Timothy , Kommoss, Stefan , Leong, Huei San, Intermaggio, Maria P., Nazeran, Tayyebeh M., Volchek, Mila, Elatre, Wafaa, Chow, Veronica, Sudderuddin, Hanwei , Mackenzie, Robertson, Leong, Samuel C.Y., Liu, Geyi, Johnson, Dustin, Chen, Billy, Group, AOCS, Alsop, Jennifer , Banerjee, Susana , Bodelón, Clara , Brand, Alison H. , Brinton, Louise A. , Carney, Michael E. , Chiew, Yoke-Eng , Cushing‐Haugen, Kara L. , Ennis, Darren , Fereday, Sián , Fortner, Renée T. , Greene, Casey S. , Hendley, Joy , Hernandez, Brenda Y. , Herpel, Esther , Jimenez‐Liñan, Mercedes , Karpinskyj, Chloe , Keeney, Gary L., Kennedy, Catherine J. , Köbel, Martin , Koziak, Jennifer M. , Lester, Jenny , Lewsley, Liz-Anne , Lissowska, Jolanta , Luk, Hugh, Mahner, Sven� , McNeish, Iain A. , Menkiszak, Janusz , Nevins, Nikilyn, Osório, Ana , Oszurek, Oleg, Pearce, Celeste Leigh , Pike, Malcolm C. , Piskorz, Anna , Rhenius, Valerie , Rodríguez‐Antona, Cristina , Sharma, Raghwa , Silva, Dilrini De , Singh, Naveena , Sinn, Hans‐Peter , Slamon, Dennis J. , Song, Honglin , Steed, Helen , Stronach, Euan A. , Thompson, Pamela J., Tołoczko, Aleksandra, Trabert, Britton , Traficante, Nadia , Tseng, Chiu-Chen , Widschwendter, Martin , Winterhoff, Boris , Beeghly‐Fadiel, Alicia, Brown, Robert , Chang‐Claude, Jenny , Chenevix‐Trench, Georgia , DeFazio, Anna , Fasching, Peter A. , García, María J. , Gayther, Simon A. , Goodman, Marc T. , Henderson, Michelle J. , Kelemen, Linda E. , Menon, Usha , Oršulić, Sandra , Wentzensen, Nicolas , Wu, Anna H. , Schildkraut, Joellen M. , Rossing, Mary Anne, Konecny, Gottfried E. , Huntsman, David G. , Huang, Ruby Yun‐Ju , Goode, Ellen L. , Ramus, Susan J. , Bowtell, David D.L. , Anglesio, Michael S. , George, Joshy , Wang, Chen , Tan, Tuan Zea , Behrens, Sabine , Bodelon, Clara , Brinton, Louise A , Fortner, Renée T , García-Donas, Jesús , Gentry‐Maharaj, Aleksandra , Glasspool, Rosalind , Greene, Casey S , Haluska, Paul , Harris, Holly R , Kaufmann, Scott H , Kennedy, Catherine J , Köbel, Martin , Koziak, Jennifer M , Lissowska, Jolanta , McNeish, Iain A , Menkiszak, Janusz , Hinsley, Samantha , Pike, Malcolm C , Rodríguez-Antona, Cristina , Sinn, Peter , Trabert, B , Widschwendter, Martin , Winham, Stacey J , Brenton, James D , Brown, Robert , Chang-Claude, Jenny , Fazio, Anna de , Fasching, Peter A , Kelemen, Linda E , Menon, Usha , Pharoah, Paul D P , Ramus, Susan J , Doherty, Jennifer A , Anglesio, Michael S , Chenevix-Trench, Georgia , Brand, Alison H , Ennis, Darren P , Traficante, Nadia , Bowtell, David D , Fereday, Sian , Hernandez, Brenda Y , Steed, Helen , Goodman, Marc T , Nevins, Nikilyn , George, Joshy , Chiu, Derek S , Chen, Stephanie , Gilks, C. Blake , Bentley, Rex C. , Senz, Janine , Lum, Amy M. , Group, AOCS, Behrens, Sabine , Cybulski, Cezary , García-Donás, Jesús , Glasspool, Rosalind , Goranova, Teodora , Harris, Holly R. , Kaufmann, Scott H. , Larson, Melissa C. , Lubiński, Jan , Macintyre, Geoff , Palacios, José , Ray-Coquard, Isabelle L. , Sherman, Mark E. , Wilkens, Lynne R. , Winham, Stacey J. , Beeghly‐Fadiel, Alicia , Benı́tez, Javier , Berchuck, Andrew , Brenton, James D. , Gronwald, Jacek , Karlan, Beth Y. , Pharoah, Paul D.P. , Doherty, Jennifer A.

Mayo Clinic

Clinical Cancer Research | June 17, 2020 | Volume: 26 | Issue: 20 | Pages: 5411-5423

10.1158/1078-0432.ccr-20-0103 | PMID 32554541 Get It

Abstract Purpose: Gene expression–based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by nonstandardized methods, which are not applicable in a clinical setting. We sought to generate a clinical grade minimal gene set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported subtype-associated features. Experimental Design: Adopting two independent approaches, we derived and internally validated algorithms for subtype prediction using published gene expression data from 1,650 tumors. We applied resulting models to NanoString data on 3,829 HGSOCs from the Ovarian Tumor Tissue Analysis consortium. We further developed, confirmed, and validated a reduced, minimal gene set predictor, with methods suitable for a single-patient setting. Results: Gene expression data were used to derive the predictor of high-grade serous ovarian carcinoma molecular subtype (PrOTYPE) assay. We established a de facto standard as a consensus of two parallel approaches. PrOTYPE subtypes are significantly associated with age, stage, residual disease, tumor-infiltrating lymphocytes, and outcome. The locked-down clinical grade PrOTYPE test includes a model with 55 genes that predicted gene expression subtype with &gt;95% accuracy that was maintained in all analytic and biological validations. Conclusions: We validated the PrOTYPE assay following the Institute of Medicine guidelines for the development of omics-based tests. This fully defined and locked-down clinical grade assay will enable trial design with molecular subtype stratification and allow for objective assessment of the predictive value of HGSOC molecular subtypes in precision medicine applications. See related commentary by McMullen et al., p. 5271